Osimertinib for lung cancer that returns after targeted therapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a targeted therapy pill called osimertinib can help people whose lung cancer has returned after they already received targeted therapy following surgery. The goal is to see if this treatment can control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC) that was surgically removed, and you took an EGFR targeted therapy pill for at least some time after surgery.
- Your cancer came back more than 3 months after you stopped that targeted therapy pill.
- A tissue or blood test has confirmed that your cancer has an EGFR mutation.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You have not already had certain treatments for the recurrence, like chemotherapy, radiation to the chest, or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This study looks at why lung cancer returns in people who took the targeted pill osimertinib after surgery. If your cancer has come back, researchers will test your tumor or blood sample to understand how the cancer changed.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.